Monte Rosa Therapeutics, Inc. (GLUE) — 10-Q Filings
All 10-Q filings from Monte Rosa Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
GLUE Swings to Nine-Month Profit on Soaring Collaboration Revenue
— Nov 6, 2025 Risk: medium
Monte Rosa Therapeutics, Inc. (GLUE) reported a significant increase in collaboration revenue for the nine months ended September 30, 2025, reaching $120.891 mi -
Monte Rosa Narrows Q2 Loss Amid R&D Spend Optimization
— Aug 7, 2025 Risk: high
Monte Rosa Therapeutics, Inc. (GLUE) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company -
Monte Rosa Therapeutics Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
Monte Rosa Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations, including r -
Monte Rosa Therapeutics Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
Monte Rosa Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and operational updates. Key finan -
Monte Rosa Therapeutics Files Q2 2024 10-Q
— Aug 8, 2024 Risk: medium
Monte Rosa Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and operational updates for the compa -
Monte Rosa Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: medium
Monte Rosa Therapeutics, Inc. (GLUE) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Monte Rosa Therapeutics, Inc. filed a 10-Q report for the peri
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX